Antibody therapy aims to keep colon cancer from returning
NCT ID NCT00002968
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase III trial tested whether adding a monoclonal antibody called edrecolomab to surgery helps people with stage II colon cancer live longer or stay cancer-free longer. About 2,100 participants were randomly assigned to receive either the antibody or no additional treatment after surgery. The study tracked survival and how long it took for the cancer to come back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- edrecolomab (monoclonal antibody 17-1A)
- What this could lead to
- If successful, this could provide an additional treatment option to reduce the risk of cancer returning after surgery for stage II colon cancer.
- What could go wrong
- This trial is completed but results may not show a clear benefit over surgery alone. Monoclonal antibodies can cause infusion reactions or allergic responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCINOUS ADENOCARCINOMA OF THE COLON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer and Leukemia Group B
Chicago, Illinois, 60606, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.